18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial-Reference-Cited by-同舟云学术

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial

Published:2016-09-01 Issue:6 Volume:23 Page:1432-1441
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Quintela-Fandino Miguel,Lluch Ana,Manso Luis,Calvo Isabel,Cortes Javier,García-Saenz José Angel,Gil-Gil Miguel,Martinez-Jánez Noelia,Gonzalez-Martin Antonio,Adrover Encarna,de Andres Raquel,Viñas Gemma,Llombart-Cussac Antonio,Alba Emilio,Guerra Juan,Bermejo Begoña,Zamora Esther,Moreno-Anton Fernando,Pernas Simon Sonia,Carrato Alfredo,Lopez-Alonso Antonio,Escudero María José,Campo Ruth,Carrasco Eva,Palacios José,Mulero Francisca,Colomer Ramon

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant TIMP‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma;Cancer Science;2024-03-12

2. Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC);Molecular Cancer Research;2023-06-21

3. PET/MRI of hypoxia and vascular function in ER-positive breast cancer: correlations with immunohistochemistry;European Radiology;2023-05-11

4. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A;Nature Communications;2022-12-07

5. The Clinical Value of Breast Specific Gamma Imaging and Positron Imaging: An Update;Seminars in Nuclear Medicine;2022-09